In addition to an exhausted or dysfunctional/tolerogenic phenotype of effector T cells in the GBM TIME, CD4+ TH are often skewed toward a TH2 phenotype, which is less effective in anti-tumor immunity compared to TH1. The gene discussed is CD4; the disease is neoplasm.